翰森制药(03692.HK)阿美乐联合化疗治疗III期临床试验达主要研究终点

阿斯达克财经
22 Oct 2024

翰森制药(03692.HK) 公布,评估阿美乐联合化疗作为局部晚期或转移性表皮生长因子受体突变非小细胞肺癌一线治疗方案的III期注册试验AENEAS2达到其主要研究终点即无进展生存期“PFS”,显示出的PFS改善具有统计学显著性和临床意义。研究详细结果将于未来医学会议发布及向监管机构递交。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-10-22 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10